Pharmafile Logo
Pharmafocus logo
Advanced Search

Daiichi Sankyo

Showing 15 posts of 56 posts found.

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

April 2, 2024
Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …

News
louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

March 4, 2024
Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …

News

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023
Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …

News

Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment

November 10, 2023
Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia

Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and …

News

AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC

October 23, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology

AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …

News

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …

News

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

September 11, 2023
Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …

News
lungs

Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC

August 23, 2023
Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan

Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …

News
index_ph001

NICE recommends Daiichi Sankyo’s cholesterol-lowering treatments for NHS England use

March 18, 2021
Daiichi Sankyo, NICE, cholesterol

NICE has recommended Daiichi Sankyo’s bempedoic acid and bempedoic acid/ezetimibe for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed …

News
enhertu

Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu approved in UK

February 16, 2021
Manufacturing and Production AstraZeneca, Cancer, Daiichi Sankyo

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted conditional authorisation in the UK as a monotherapy for the …

News
astrazeneca_sign_sky

EU approves breast cancer drug Enhertu

January 20, 2021
Research and Development AstraZeneca, Daiichi Sankyo

The EU has granted AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) conditional approval as a monotherapy for the treatment of …

News
index_ph001

Daiichi Sankyo’s Nilemdo “significantly” reduces cholesterol levels at ESC 2020

September 1, 2020
Manufacturing and Production, Research and Development Daiichi Sankyo, Nilemdo, pharma

Daiichi Sankyo has unveiled promising new benefit for Nilemdo (bempedoic acid) at the ESC Congress 2020 over the weekend for …

News
shutterstock_273326141

AstraZeneca partners with Daichii Sankyo in potential $6bn cancer drug deal

July 27, 2020
Research and Development, Sales and Marketing AstraZeneca, Daiichi Sankyo, partnership, pharma

AstraZeneca and Daiichi Sankyo have joined forces to drive the development and commercialisation of the latter’s DS-1062, a trophoblast cell-surface …

News
index_ph001

Daiichi Sankyo’s Turalio becomes first FDA-approved therapy for rare tumour

August 5, 2019
Sales and Marketing Cancer, Daiichi Sankyo, FDA, Turalio, US, pharma, rare cancer

Daiichi Sankyo has seen its CSF1R inhibitor Turalio (pexidartinib) approved by the FDA in the treatment of symptomatic tenosynovial giant …

News
index_ph001

Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel

May 15, 2019
Research and Development, Sales and Marketing Daiichi Sankyo, FDA, pexidartinib, pharma, quizartinib

Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024